ADC Therapeutics (ADCT) FCF Margin (2021 - 2026)
ADC Therapeutics (ADCT) posted FCF Margin of 142.64% for Q1 2026, up 20.92% sequentially from 180.37% in Q3 2025, and up 10309.0% YoY from N/an in Q1 2025.
ADC Therapeutics (ADCT) FCF Margin (2021 - 2026) Analysis & Trends
ADC Therapeutics has reported FCF Margin for 6 years, with the latest figure at 142.64% in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -388.28% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 25.68% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 22.62% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -22.35% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 70.82% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 41.07% |
| 10 | ADC Therapeutics | 148.95 Mn | -70.15 Mn | 17.14 Mn | -61.34% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -61.34% |
| Mar 31, 2026 | -142.64% |
| Sep 30, 2025 | -180.37% |
| Jun 30, 2025 | -127.86% |
| Mar 31, 2025 | -245.73% |
| Sep 30, 2024 | -136.80% |
| Jun 30, 2024 | -188.83% |
| Mar 31, 2024 | -247.19% |
| Sep 30, 2023 | -257.60% |
| Jun 30, 2023 | -187.73% |
| Mar 31, 2023 | -86.39% |
| Sep 30, 2022 | 2.62% |
| Jun 30, 2022 | -306.86% |
| Mar 31, 2022 | -73.36% |
| Sep 30, 2021 | -456.32% |
| Jun 30, 2021 | -1,568.03% |